Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.

Guay AT, Perez JB, Fitaihi WA, Vereb M.

Endocr Pract. 2000 Mar-Apr;6(2):132-8.

PMID:
11421528
2.
3.

[Testosterone and the prostate].

Sperling H, Rossi R, Lümmen G, Rübben H.

Urologe A. 2004 Sep;43(9):1092-6. Review. German.

PMID:
15368045
4.

Clinical experiences with testosterone therapy: prostate safety.

Ebert T.

Aging Male. 2004 Dec;7(4):304-11. Review.

PMID:
15799126
5.

The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.

Ebert T, Jockenhövel F, Morales A, Shabsigh R.

Eur Urol. 2005 Feb;47(2):137-46. Review.

PMID:
15661407
6.

[Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].

Rinnab L, Gust K, Hautmann RE, Küfer R.

Urologe A. 2009 May;48(5):516-22. doi: 10.1007/s00120-009-1954-z. Review. German.

PMID:
19296069
7.

The role of testosterone replacement therapy following radical prostatectomy.

Khera M, Lipshultz LI.

Urol Clin North Am. 2007 Nov;34(4):549-53, vi. Review.

PMID:
17983894
8.

Testosterone therapy for men at risk for or with history of prostate cancer.

Morgentaler A.

Curr Treat Options Oncol. 2006 Sep;7(5):363-9. Review.

PMID:
16904053
10.

The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.

Cui Y, Zong H, Yan H, Zhang Y.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):132-43. doi: 10.1038/pcan.2013.60. Epub 2014 Jan 21. Review.

PMID:
24445948
11.

Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.

Gray H, Seltzer J, Talbert RL.

Am J Health Syst Pharm. 2015 Apr 1;72(7):536-41. doi: 10.2146/ajhp140128. Review.

PMID:
25788507
12.

The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.

Cui Y, Zong H, Yang C, Yan H, Zhang Y.

Int Urol Nephrol. 2013 Aug;45(4):979-87. doi: 10.1007/s11255-013-0477-0. Epub 2013 Jun 1. Review.

PMID:
23728850
13.

Prostate cancer risk in testosterone-treated men.

Raynaud JP.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):261-6. Review.

PMID:
17113983
14.

[Patient with TDS and increased PSA (implications in prostate biopsy)].

García-Cruz E.

Arch Esp Urol. 2013 Sep;66(7):652-6. Review. Spanish.

PMID:
24047622
15.

Testosterone deficiency syndrome: treatment and cancer risk.

Raynaud JP.

J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):96-105. doi: 10.1016/j.jsbmb.2009.01.014. Epub 2009 Jan 30. Review.

PMID:
19429438
17.

Current state of practice regarding testosterone supplementation therapy in men with prostate cancer.

Kovac JR, Pan MM, Lipshultz LI, Lamb DJ.

Steroids. 2014 Nov;89:27-32. doi: 10.1016/j.steroids.2014.07.004. Epub 2014 Jul 27. Review.

18.

The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.

Klap J, Schmid M, Loughlin KR.

J Urol. 2015 Feb;193(2):403-13. doi: 10.1016/j.juro.2014.07.123. Epub 2014 Sep 28. Review.

PMID:
25260832
19.

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.

Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society.

J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59. doi: 10.1210/jc.2009-2354. Review.

PMID:
20525905
20.

Late-Onset Hypogonadism and Testosterone Replacement in Older Men.

Bhattacharya RK, Bhattacharya SB.

Clin Geriatr Med. 2015 Nov;31(4):631-44. doi: 10.1016/j.cger.2015.07.001. Review. Erratum in: Clin Geriatr Med. 2016 Feb;32(1):xv.

PMID:
26476121

Supplemental Content

Support Center